Synthetic therapeutic peptides: science and market.

By P. Vlieghe, V. Lisowski, Jean Martinez, M. Khrestchatisky. Drug Discovery Today, 2010

1,377 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Molecular Biology, Organic Chemistry

View Paper: https://www.semanticscholar.org/paper/5d7fac95a056d07c953252cf344e62128d4468f8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

1. Lim Heo
2. O. Schueler‐Furman
3. Chaok Seok
4. Pierre Tufféry

In Molecular Biology

1. O. Schueler‐Furman
2. Lim Heo
3. Pierre Thévenet
4. Barak Raveh
5. Nir London
6. Philippe Derreumaux
7. Pierre Tufféry
8. Hasup Lee

In Organic Chemistry

1. Lim Heo

Citations in the corpus

• Rethinking amide bond synthesis (2011, background): “In practice, large-scale peptide manufacturing presents several challenges that are not well served by traditional solid-phase peptide synthesi”
• Rosetta FlexPepDock ab-initio: Simultaneous Folding, Docking and Refinement of Peptides onto Their Receptors (2011, background): “[6]), flexible peptides are implicated in human disease and cancer [1], and therefore provide attractive leads for the design of inhibitory peptides and small molecule drugs [7,8,9,10,11,12].”
• GalaxyPepDock: a protein–peptide docking tool based on interaction similarity and energy optimization (2015, background): “Because of the small sizes of protein–peptide interfaces, such interactions can be modulated by small chemicals or synthetic peptides (7,8).”
• CancerPPD: a database of anticancer peptides and proteins (2014, background): “With several advantages, including high specificity, low intrinsic toxicity, high tissue penetration and ease of modifications, peptides have become the preferred choice as therapeutics compared to small molecules and antibody (4,5).”
• In Silico Approach for Predicting Toxicity of Peptides and Proteins (2013, background): “As a result of these efforts, rate of therapeutic peptides entering into clinical trials has improved significantly over the decade [1].”
• Basics and recent advances in peptide and protein drug delivery (2013, positive): “Other peptides such as somatostatin and encephalin have demonstrated similar characteristics and improved oral absorption after cyclization [31,32].”
• In Silico Models for Designing and Discovering Novel Anticancer Peptides (2013, background): “The peptide-based therapeutics is gaining tremendous interest now-adays 2,3 , which has been reflected in the papers published in the last five years.”
• The Future of Peptide‐based Drugs (2013, background): “Our analysis of structural data for a well-documented subset of these (6) shows that the majority of current peptide-based products are at the smaller end of the size spectrum (8–10 amino acids), although peptides up to 45 amino acids are currently on the market (Figure 2).”
• Antimicrobial Peptides: An Emerging Category of Therapeutic Agents (2016, background): “Altogether, this reduces the safety risk and risk of complications caused by metabolites (Vlieghe et al., 2010).”
• PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides (2012, background): “First, recent advances in peptide chemistry and delivery have overcome the traditional limitations of peptides as drug candidates (1).”
• Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials (2020, background): “Compared with monoclonal antibodies, the peptides and small molecule drugs do not have the limitations of monoclonal antibodies as mentioned above.(206) Chang et al.”